LEADER 03809nam  2200589Ia 450 
001 9910780208103321
005 20230617011757.0
010   $a1-280-01133-5
010   $a92-4-068157-4
010   $a9786610011339
035   $a(CKB)111087027685714
035   $a(EBL)284793
035   $a(OCoLC)191039475
035   $a(SSID)ssj0000271407
035   $a(PQKBManifestationID)11192927
035   $a(PQKBTitleCode)TC0000271407
035   $a(PQKBWorkID)10293689
035   $a(PQKB)10729267
035   $a(MiAaPQ)EBC284793
035   $a(Au-PeEL)EBL284793
035   $a(CaPaEBR)ebr10040297
035   $a(EXLCZ)99111087027685714
100   $a20030508d2003      uh             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aWHO Expert Committee on Specifications for Pharmaceutical Preparations$b[electronic resource] $ethirty-seventh report
210   $aGeneva $cWorld Health Organization$d2003
215   $a1 online resource (145 p.)
225 1 $aWHO technical report series,$x0512-3054 ;$v908
300   $aDescription based upon print version of record.
311   $a92-4-120908-9 
311   $a0-585-49271-9 
327   $a1. Introduction -- 2. General policy -- 3. Quality control--specifications and tests -- 4. Quality control--international reference materials -- 5. Quality control--national laboratories -- 6. Quality assurance--good manufacturing practices (GMP) -- 7. Quality assurance--inspection -- 8. Quality assurance--distribution and trade-related -- 9. Quality assurance--risk analysis -- 10. Quality assurance--drug supply -- 11. Quality assurance--storage -- 12. International Nonproprietary Names (INNs) Programme -- 13. Miscellaneous -- Annex 1. Recommendations on risk of transmitting animal spongiform encephalopathy agents via medicinal products -- Annex 2. The International Pharmacopoeia: revised concepts and future perspectives -- Annex 3. Guidelines on good manufacturing practices for radiopharmaceutical products -- Annex 4. Good manufacturing practices for pharmaceutial products: main principles -- Annex 5. Model certificate of good manufacturing practices -- Annex 6. Guidance on good manufacturing practices (GMP): inspection report -- Annex 7. Application of hazard analysis and critical control point (HACCP) method to pharmaceuticals -- Annex 8. Procedure for assessing the acceptability, in principle, of pharmaceutical products for purchase by United Nations agencies -- Annex 9. Guide to good storage practices for pharmaceuticals.
330   $aThis report presents the recommendations of an international group of experts convened by the World Health Organization to consider matters concerning the quality assurance of pharmaceuticals and specifications for drug substances and dosage forms. The report is complemented by a number of annexes. These include: a list of available international chemical reference substances and international infrared spectra; supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms; updated supplementary guideli
410  0$aTechnical report series (World Health Organization) ;$v908.
606   $aDrugs$xStandards$vCongresses
606   $aDrugs$xSpecifications$vCongresses
606   $aPharmaceutical industry$xQuality control$vCongresses
615  0$aDrugs$xStandards
615  0$aDrugs$xSpecifications
615  0$aPharmaceutical industry$xQuality control
676   $a615.19
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910780208103321
996   $aWHO Expert Committee on Specifications for Pharmaceutical Preparations$91917970
997   $aUNINA